Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $62.26 and last traded at $58.25, with a volume of 2085356 shares changing hands. The stock had previously closed at $47.13.
Gemini Therapeutics Price Performance
The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -47.13 and a beta of -0.12. The business’s 50-day moving average price is $48.56 and its two-hundred day moving average price is $42.66.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
- Five stocks we like better than Gemini Therapeutics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Intel: Is Now the Time to Be Brave?Â
- Differences Between Momentum Investing and Long Term Investing
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- How to Choose Top Rated Stocks
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
